First Clinical Trial of Vosoritide for Children with Hypochondroplasia Shows Increased Growth
The first global phase 2 study of vosoritide showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of short stature in children, according to a paper recently published in eClinicalMedicine. The clinical trial is funded by BioMarin. Researchers led by Andrew Dauber, MD, chief of Endocrinology at Children’s...
Endocrine Society Experts Leverage Media to Improve Access to Care and Raise Awareness of EDCs
The EPA Takes Steps to Reduce PFAS Exposures in Drinking Water
These steps are in line with Endocrine Society recommendations. On April 10, the Biden-Harris Administration issued the first-ever national, legally enforceable drinking water standard to protect communities from exposure to harmful per-and polyfluoroalkyl substances (PFAS), also known as ‘forever chemicals.’ As part of the administration’s commitment to combatting PFAS, the Environmental Protection Agency (EPA) announced...